Treatment concerns patients with IDH1-mutated acute myeloid leukaemia and IDH1-mutated cholangiocarcinoma
News
Ariceum and UCB link up to take on immune-related diseases
The companies will use proprietary technology to enable the discovery of peptide-radioisotope conjugates
NHS in Scotland receives Pfizer’s migraine treatment
Patients living with the debilitating impacts of migraine attacks will be able to access Vydura
Cambridge University receives first synthesized DNA from Evonetix
Transfer marks start of vital development stage as company expands its range of synthesized DNA
Positive opinion for Gilead’s Hepcludex
The therapy treats adults with chronic hepatitis delta virus and compensated liver disease
First patient dosed in pivotal CureVac flu vaccine study
Modified influenza vaccine candidates have been developed in collaboration with GSK
Positive opinion for Gilead’s Hepcludex
The vital recommendation ensures marketing authorisation for treating the hepatitis delta virus
Kry showcases digital care pathways
Systems will support millions of patients with chronic respiratory conditions throughout Europe
BioSenic progresses cGvHD system and submits patent to EPO
Patent will allow the development of an industrial biomarker analysis kit which could be available worldwide
Endogena finalises enrolment for retinitis pigmentosa trial
The treatment is a small molecule that activates endogenous retinal stem and progenitor cells
Vicore begins vital endothelial dysfunction study
The wide-ranging research aims to unlock the potential of angiotensin II type 2 receptor agonists
Otsuka’s Lupkynis receives NICE green light
Recommendation applies across England and Wales and the treatment is available now
VYNE and Tay Therapeutics reach licence agreement
Deal involves an oral BET inhibitor which treats fibrotic and immuno-inflammatory disorders
SporeGen and Destiny advance research collaboration
Duo have partnered on developing a biotherapeutic therapy for flu and COVID-19
NICE approves expanded use of Yescarta and Tecartus
Kite’s two CAR T-Cell therapies involve treating several different types of blood cancer
